Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein

Folch, Jaume; Ettcheto, Miren; Петров, Д. С.; Abad, Sònia; Pedrós, Ignacio; Marin, Miguel; Olloquequi, Jordi; Camins, Antoni

doi:10.1016/j.nrleng.2015.03.019

Cited by 71 publications

(56 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no significant evidence that AD pathology is present in the brain many years before the clinical manifestation of the disease, such as amyloid plaques, cerebral infarction, and gray matter atrophy. 1,2 When considering hippocampal atrophy as a baseline AD status, the association of APOE-ε4…”

Section: Discussionmentioning

confidence: 99%

“…Alzheimer's disease (AD) is a progressive brain disorder that results in loss of memory, associated with unusual behavior, personality changes, and an irreversible decline in cognitive skills. [1][2][3] As a matter of fact, AD is the most common form of dementia in elderly people worldwide. Approximately 13% of people over the age of 65 years and 45% over the age of 85 years are subjected to AD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The association between the ApoE polymorphisms and the MRI‐defined intracranial lesions in a cohort of southern China population

Yang

Lei

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundThe apolipoprotein E (APOE) ε4 allele is considered as a risk factor for Alzheimer's disease (AD). However, the association of APOE allele with MRI evidence of intracranial lesions has not been well understood.MethodsQuantitative real‐time PCR was performed to detect the APOE genotype; MRI was examined for intracranial lesions. Their association was evaluated in a cohort of 226 AD patients and 2607 healthy individuals in southern China.ResultsThe frequencies of ε2, ε3, and ε4 alleles were 8.0%, 82.9%, and 9.1% in the whole study population. The frequency of APOE‐ε4 allele was significantly higher in the AD subjects than that in the control group (14.4% vs 8.6%, P < 0.001). We found that brain atrophy occurred at a rate of 12.3% in ε4 allele group vs 8.5% in non‐ε4 genotype group, with a significance of P = 0.008. Severe brain atrophy occurred at a rate of 1.0% in ε4 allele group vs 0.2% in non‐ε4 genotype group (P = 0.011). The individuals carrying APOE ε4/ε4 had an odds ratio (OR) of 7.64 (P < 0.01) for developing AD, while the APOE ε3/ε4 gene carriers had an OR of 1.47 (P = 0.031) and the OR in APOE ε2/ε3 carriers is 0.81 (P = 0.372). Interestingly, we found that the risk of ε4/ε4 allele carrier developing AD was significantly higher in male (P < 0.001) than female (P = 0.478).ConclusionCompared to ε2 and ε3 alleles, the presence of APOE‐ε4 allele might increase the risk for AD in a dose‐dependent manner in southern China. Moreover, the presence of APOE‐ε4 allele results in a higher incidence of brain atrophy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The association between the ApoE polymorphisms and the MRI‐defined intracranial lesions in a cohort of southern China population

Yang

Lei

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Rei ka lin gi to les ni se lek ty vios ga ma sek re tazës in hi bi ci jos ty ri mai, to dël pra dë ta ty ri në ti ga ma sek re tazës mo du lia to rius [24]. Pa ste bë jus, kad ne ste roi di niai vais tai nuo uþ de gi mo su ma þi na Ab42 kie ká pe lëms, bu vo pra dë ti ne ste roi di niø vais tø nuo uþ de gi mo, kaip ga ma sekre ta zës mo du lia to riø, ty ri mai, ta èiau jie ne pa ro dë efek tyvu mo [31].…”

Section: Beta Amiloido Gamybos Maþinimas Beta Ir Gama Sekretaziø Inhiunclassified

“…Gan te re nu ma bas ska ti na se ni li niø plokð te liø ar dy mà, ak ty vuo da mas mik ro gli jà ir fa go ci to zae, ta èiau ne si jun gia su plaz mos be ta ami loi du. I fa zës ty ri muo se bu vo ge rai tole ruo ja mas, ta èiau da liai pa cien tø ste bë ti pa ki ti mai vaiz diniuo se ty ri muo se (ARIA-E) [31,32]. 2015 m. bu vo su stabdy tas III fa zës kli ni ki nis ty ri mas, nes vais tas ne pa ro dë reikia mo efek to.…”

Section: Amiloido Beta ðAlinimo Skatinimas Naudojant Pasyvià Ir Aktyunclassified

“…Jis bu vo su kur tas pa ða lin ti be ta ami loi do san kau pas, pa ska ti nant efek to ri niø mik rogli jos làs te liø funk ci jas, sti mu liuo jant fa go ci to zae, bet vengiant uþ de gi mi niø ci to ki nø ið sky ri mo ir va zo ge ni nës edemos [31,34]. Efek ty vu mo ty ri muo se ste bë ta, kad di des nës vais to do zës yra efek ty ves nës, ir ðiuo me tu at lie ka mi III fazës kli ni ki niai ty ri mai (CREAD, CREAD2 ir ki ti) pro dromi nei AL, leng vai ir vi du ti nio sun ku mo AL bei au to so miniu do mi nan ti niu bû du pa vel di mai AL gy dy ti [14].…”

Section: Amiloido Beta ðAlinimo Skatinimas Naudojant Pasyvià Ir Aktyunclassified

See 1 more Smart Citation

In search of Alzheimer’s disease treatment methods: trends of clinical trials

Pakulaitė

Regelskytė

Audronytė

et al. 2018

View full text Add to dashboard Cite

Vilniaus universiteto Medicinos fakulteto Klinikinës medicinos instituto Neurologijos ir neurochirurgijos klinika ÁVADASAlz hei me rio li ga (AL) -lë ti në pro gre suo jan ti, ne gráþ ta mø po ky èiø sme ge ny se su ke lian ti li ga [1]. Tai daþ niau sia demen ci jos prie þas tis, su da ran ti 60-70 % vi sø de men ci jø, o jos pa pli ti mas itin di dë ja il gë jant gy ve ni mo truk mei [2,3]. AL su ke lia di de lae eko no mi nae nað tà, taip pat tam pa vis daþ -nes ne mir ties prie þas ti mi [3]. Stu di jø duo me ni mis, mir tingu mas nuo in sul to ir ðir dies li gø ma þë ja, ta èiau AL, kaip mir ties prie þas tis tarp vy res niø nei 75 me tø am þiaus pa cientø, mi n i ma jau ne ðeð to je, o tre èio je vie to je pa gal daþ ná po kar dio vas ku li niø ir ce reb ro vas ku li niø li gø bei vë þio [3,4]. AL gy dy mo kli ni ki niø ty ri mø pra dþia lai ko mi 1980-1990 m., kai pra dë ti nau do ti cho li nes te ra zës in hi bito riai [5]. 1974 m. Drach man ir Le a vitt su sie jo cen tri niø cho li ner gi niø neu ro nø pa þei di mà su at min ties blo gë ji mu ir am þiu mi, o vë les në se stu di jo se Da vis ir Ma lo ney ap ra ðë cho li ner gi nio Mei ner to bran duo lio (angl. nu cleus basalis of Meynert) pa þei di mà pa cien tams, ser gan tiems AL [6,7]. Ma ny ta, kad cho li ner gi nës sis te mos pa þei di mas, ser gant AL, pa na ðus á do pa mi ner gi nës sis te mos pa þei di mà, sergant Par kin so no li ga [8]. Pir mà já cho li nes te ra zës in hi bi toriø tak ri nà leng vai ir vi du ti nio sun ku mo Alz hei me rio ti po de men ci jai gy dy ti 1993 m. áre gist ra vo JAV Mais to ir vaistø ad mi nist ra ci ja (angl. Food and Drug Ad min is tra tion, FDA), ta èiau jis ne be nau do ja mas dël ne pa gei dau ja mø reið ki niø (virð ki na mo jo trak to simp to mø) ir ma þo efek tyvu mo [9,10]. Nuo to lai ko bu vo at lik ta ir ðiuo me tu vyks ta dau gy bë kli ni ki niø ty ri mø, ta èiau tik 3 cho li nes te ra zës inhi bi to riai (do ne pe zi lis, ri vas tig mi nas (jo pe ro ra li në ir trans der ma li në for mos), ga lan ta mi nas) ir glu ta ma ter gi nae sis te mà vei kian tis me man ti nas ty ri muo se pa ro dë pa kan kamà efek ty vu mà bei sau gu mà ir bu vo áre gist ruo ti gy dy ti AL [10]. Ðie vais tai, skir ti simp to mi niam AL gy dy mui, ðiek tiek pa leng vi na li gos kli ni ki nae ið raið kà, ta èiau jø efek ty vumas në ra di de lis, jie ne vei kia li gos prie þas ties ir ne su stabdo li gos pro gre sa vi mo [10,11]. Pas ku ti nis vais tas AL gydy ti -me man ti nas -Eu ro po je bu vo áre gist ruo tas 2002 m., o JAV -2003 m. [10]. Vais tø, skir tø AL gy dy ti, kli ni ki niai ty ri mai vyks ta jau ke lis de ðimt me èius, ta èiau 15 me tø neran da ma nau jø efek ty viø ir sau giø vais tø.Pas ta rà já de ðimt me tá dau giau sia kli ni ki niø ty ri mø at lieka ma su vais tais, po ten cia liai ga lin èiais mo di fi kuo ti AL ei - Adresas: Gy të Pa ku lai të Vil niaus uni ver si te to li go ni nës San ta ros kli ni kos, Neurologijos cen tras San ta rið kiø g. 2, LT-08661 Vil nius El. pa ðtas gyte.pakulaite@gmail.comSan tra...

show abstract